Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

I-Mab Forms Discovery Partnerships with mRNA and AI Companies

publication date: Jul 9, 2021

Shanghai I-Mab  announced two partnerships to develop oncology candidates with China biopharmas that offer novel discovery technologies. The company will work to develop new therapeutics with Immorna, a Hangzhou mRNA biotech company, and neoX Biotech, a Beijing AI-based R&D biotech. I-Mab will use Immorna's self-replicating mRNA platform, and it will identify up to 10 novel biologic candidates based on neoX's proprietary AI algorithm. Earlier this year , I-Mab announced collaborations with Complix for cell-penetrating antibodies and Affinity for masking antibodies. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital